MY195013A - Tetrahydroquinoline derivatives as p2x7 receptor antagonists - Google Patents
Tetrahydroquinoline derivatives as p2x7 receptor antagonistsInfo
- Publication number
- MY195013A MY195013A MYPI2019004850A MYPI2019004850A MY195013A MY 195013 A MY195013 A MY 195013A MY PI2019004850 A MYPI2019004850 A MY PI2019004850A MY PI2019004850 A MYPI2019004850 A MY PI2019004850A MY 195013 A MY195013 A MY 195013A
- Authority
- MY
- Malaysia
- Prior art keywords
- receptor antagonists
- tetrahydroquinoline derivatives
- present
- tetrahydroquinoline
- derivatives
- Prior art date
Links
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title abstract 2
- 101710189965 P2X purinoceptor 7 Proteins 0.000 title abstract 2
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017047794 | 2017-03-13 | ||
PCT/JP2018/009627 WO2018168818A1 (en) | 2017-03-13 | 2018-03-13 | Tetrahydroquinoline derivatives as p2x7 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MY195013A true MY195013A (en) | 2022-12-31 |
Family
ID=63523432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2019004850A MY195013A (en) | 2017-03-13 | 2018-03-13 | Tetrahydroquinoline derivatives as p2x7 receptor antagonists |
Country Status (26)
Country | Link |
---|---|
US (3) | US11077100B2 (en) |
EP (1) | EP3609868B1 (en) |
JP (1) | JP6823196B2 (en) |
KR (1) | KR102285817B1 (en) |
CN (1) | CN110382466B (en) |
AU (1) | AU2018235561B2 (en) |
BR (1) | BR112019017333A2 (en) |
CA (1) | CA3049192C (en) |
DK (1) | DK3609868T3 (en) |
ES (1) | ES2963044T3 (en) |
FI (1) | FI3609868T3 (en) |
HR (1) | HRP20231682T1 (en) |
HU (1) | HUE064575T2 (en) |
LT (1) | LT3609868T (en) |
MX (1) | MX2019010993A (en) |
MY (1) | MY195013A (en) |
PH (1) | PH12019501418A1 (en) |
PL (1) | PL3609868T3 (en) |
PT (1) | PT3609868T (en) |
RS (1) | RS64995B1 (en) |
RU (1) | RU2724350C1 (en) |
SA (1) | SA519410097B1 (en) |
SG (1) | SG11201906627YA (en) |
SI (1) | SI3609868T1 (en) |
TW (1) | TWI764999B (en) |
WO (1) | WO2018168818A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY195013A (en) * | 2017-03-13 | 2022-12-31 | Raqualia Pharma Inc | Tetrahydroquinoline derivatives as p2x7 receptor antagonists |
CN112505213B (en) * | 2019-12-19 | 2022-04-08 | 金陵药业股份有限公司 | Method for detecting components of oral liquid capable of clearing heat, nourishing yin, promoting blood circulation and removing blood stasis |
JPWO2022114122A1 (en) | 2020-11-30 | 2022-06-02 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6956047B1 (en) | 1995-06-06 | 2005-10-18 | Pfizer Inc. | Corticotropin releasing factor antagonists |
US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
WO2001007051A1 (en) | 1999-07-23 | 2001-02-01 | Merck & Co., Inc. | Prenyl-protein transferase inhibitors |
AP2002002583A0 (en) | 2000-01-18 | 2002-09-30 | Pfizer Prod Inc | Corticotropin releasing factor antagonists. |
NZ520075A (en) | 2000-02-04 | 2004-02-27 | Pfizer Prod Inc | Heterocyclic amide derivatives |
GB0312368D0 (en) * | 2003-05-30 | 2003-07-02 | Univ Aston | Novel ureido- and amido-pyrazolone derivatives |
GB0312609D0 (en) * | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
SE0302139D0 (en) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
AU2005206571B8 (en) | 2004-01-23 | 2010-09-02 | Amgen Inc. | Compounds and methods of use |
US20080076924A1 (en) | 2006-06-30 | 2008-03-27 | Patrick Betschmann | Piperazines as P2X7 antagonists |
UA100227C2 (en) * | 2006-07-06 | 2012-12-10 | Глаксо Груп Лімітед | Substituted n-phenylmethyl-5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
JP2010518125A (en) | 2007-02-12 | 2010-05-27 | インターミューン・インコーポレーテッド | Novel inhibitor of hepatitis C virus replication |
GB0705882D0 (en) | 2007-03-27 | 2007-05-02 | Glaxo Group Ltd | Novel compounds |
WO2008124153A1 (en) * | 2007-04-10 | 2008-10-16 | H. Lundbeck A/S | Heteroaryl amide analogues as p2x7 antagonists |
EP2215054B8 (en) | 2007-11-13 | 2012-02-08 | Evotec AG | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
JP2011509296A (en) | 2008-01-09 | 2011-03-24 | レノビス, インコーポレイテッド | Amide derivatives as ion channel ligands and pharmaceutical compositions and methods using the same |
MX2011012712A (en) | 2009-05-29 | 2012-01-30 | Raqualia Pharma Inc | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers. |
AU2012288511A1 (en) | 2011-07-22 | 2014-03-13 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as P2X7 receptor antagonists |
MX2014004979A (en) | 2011-10-24 | 2014-10-24 | Abbvie Inc | Methanol derivatives as trpv3 modulators. |
US9409917B2 (en) | 2012-01-20 | 2016-08-09 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
EP2846801B1 (en) | 2012-05-09 | 2017-04-05 | Merck Sharp & Dohme Corp. | Pyridine cgrp receptor antagonists |
WO2014025651A1 (en) | 2012-08-06 | 2014-02-13 | Amgen Inc. | Chroman derivatives as trpm8 inhibitors |
TWI598325B (en) * | 2012-10-12 | 2017-09-11 | H 朗德貝克公司 | Benzamides |
AR094053A1 (en) * | 2012-12-18 | 2015-07-08 | Actelion Pharmaceuticals Ltd | DERIVATIVES OF INDOL CARBOXAMIDE AS ANTAGONISTS OF THE P2X RECEIVER |
CN104918617B (en) | 2013-01-22 | 2017-05-10 | 埃科特莱茵药品有限公司 | Heterocyclic amide derivatives as p2x7 receptor antagonists |
ES2616883T3 (en) | 2013-01-22 | 2017-06-14 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
JO3773B1 (en) | 2013-03-14 | 2021-01-31 | Janssen Pharmaceutica Nv | P2x7 modulators |
EP3152192A1 (en) | 2014-06-05 | 2017-04-12 | Merck Patent GmbH | Novel quinoline derivatives and their use in neurodegenerative diseases |
RU2017105133A (en) | 2014-07-31 | 2018-08-28 | Мерк Патент Гмбх | INDOLYSINE DERIVATIVES THAT USE FOR NEURODEGENERATIVE DISEASES |
EA201790600A1 (en) | 2014-09-12 | 2017-07-31 | Янссен Фармацевтика Нв | MODULATING P2X7 N-ACYL TRIAZOLOPIRASINS |
MY195013A (en) * | 2017-03-13 | 2022-12-31 | Raqualia Pharma Inc | Tetrahydroquinoline derivatives as p2x7 receptor antagonists |
-
2018
- 2018-03-13 MY MYPI2019004850A patent/MY195013A/en unknown
- 2018-03-13 SG SG11201906627YA patent/SG11201906627YA/en unknown
- 2018-03-13 JP JP2019550864A patent/JP6823196B2/en active Active
- 2018-03-13 HU HUE18768497A patent/HUE064575T2/en unknown
- 2018-03-13 PT PT187684972T patent/PT3609868T/en unknown
- 2018-03-13 MX MX2019010993A patent/MX2019010993A/en unknown
- 2018-03-13 WO PCT/JP2018/009627 patent/WO2018168818A1/en active Application Filing
- 2018-03-13 DK DK18768497.2T patent/DK3609868T3/en active
- 2018-03-13 US US16/491,119 patent/US11077100B2/en active Active
- 2018-03-13 SI SI201831014T patent/SI3609868T1/en unknown
- 2018-03-13 CN CN201880016054.3A patent/CN110382466B/en active Active
- 2018-03-13 HR HRP20231682TT patent/HRP20231682T1/en unknown
- 2018-03-13 PL PL18768497.2T patent/PL3609868T3/en unknown
- 2018-03-13 TW TW107108410A patent/TWI764999B/en active
- 2018-03-13 BR BR112019017333-1A patent/BR112019017333A2/en active Search and Examination
- 2018-03-13 ES ES18768497T patent/ES2963044T3/en active Active
- 2018-03-13 LT LTEPPCT/JP2018/009627T patent/LT3609868T/en unknown
- 2018-03-13 RU RU2019131685A patent/RU2724350C1/en active
- 2018-03-13 EP EP18768497.2A patent/EP3609868B1/en active Active
- 2018-03-13 KR KR1020197029982A patent/KR102285817B1/en active IP Right Grant
- 2018-03-13 RS RS20231238A patent/RS64995B1/en unknown
- 2018-03-13 CA CA3049192A patent/CA3049192C/en active Active
- 2018-03-13 AU AU2018235561A patent/AU2018235561B2/en active Active
- 2018-03-13 FI FIEP18768497.2T patent/FI3609868T3/en active
-
2019
- 2019-06-20 PH PH12019501418A patent/PH12019501418A1/en unknown
- 2019-09-10 SA SA519410097A patent/SA519410097B1/en unknown
-
2020
- 2020-12-04 US US17/112,097 patent/US11439633B2/en active Active
-
2022
- 2022-07-22 US US17/871,423 patent/US20230149382A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016011632A (en) | Azaspiro derivatives as trpm8 antagonists. | |
MX2020010484A (en) | Substituted heterocyclyl derivatives as cdk inhibitors. | |
IL257481B (en) | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | |
PH12018500259A1 (en) | Muscarinic agonists | |
EA033544B1 (en) | Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors | |
PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
MX2019002057A (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate. | |
SA519410097B1 (en) | Tetrahydroquinoline derivatives as p2x7 receptor antagonists | |
EA033281B1 (en) | Azabenzimidazoles and their use as ampa receptor modulators | |
MX2017001103A (en) | Indolizine derivatives which are applicable to neurodegenerative diseases. | |
NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
MX2020011668A (en) | Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases. | |
MY201535A (en) | Therapeutic compounds | |
NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
MX2017008495A (en) | New benzimidazole derivatives as antihistamine agents. | |
EA201892529A1 (en) | COMBINATION OF PURE ANTAGONISTS OF 5-HTRECEPTORS WITH ACETYLHOLINESTERASE INHIBITORS | |
EP3248603A4 (en) | Pharmaceutical composition for prevention, treatment or delay of alzheimer's disease or dementia containing g protein-coupled receptor 19 agent as active ingredient | |
WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
EA201691796A1 (en) | N-SUBSTITUTED ASYMMETRIC UREA AND THEIR APPLICATION IN MEDICINE | |
EA201892583A1 (en) | COMBINATION OF PURE ANTAGONISTS OF A 5-HT RECEPTOR WITH AN ANTAGONIST OF NMDA RECEPTOR | |
PH12017501736A1 (en) | Indole derivatives | |
EA201991286A1 (en) | A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN | |
WO2018033742A3 (en) | Cytisine derivatives for the treatment of addiction |